


Searching News Database: atopic dermatitis
HSMN NewsFeed - 12 Dec 2025
Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
HSMN NewsFeed - 13 Dec 2023
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
HSMN NewsFeed - 18 Oct 2022
Dr. Brett King Joins BiologicsMD as Senior Scientific Advisor and Member of the Scientific Advisory Board
Dr. Brett King Joins BiologicsMD as Senior Scientific Advisor and Member of the Scientific Advisory Board
HSMN NewsFeed - 15 Sep 2022
Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment
Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment
HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
HSMN NewsFeed - 23 Jun 2020
Ortho Dermatologics Launches ARAZLO(TM) (tazarotene) Lotion, 0.045%, In The United States
Ortho Dermatologics Launches ARAZLO(TM) (tazarotene) Lotion, 0.045%, In The United States
HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
HSMN NewsFeed - 18 May 2020
Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment
Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment
HSMN NewsFeed - 24 Aug 2018
Ortho Dermatologics Receives FDA Approval For ALTRENO(TM) (tretinoin 0.05%) Lotion For Acne
Ortho Dermatologics Receives FDA Approval For ALTRENO(TM) (tretinoin 0.05%) Lotion For Acne
HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
HSMN NewsFeed - 22 Jan 2018
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
HSMN NewsFeed - 14 Sep 2016
DS Biopharma Announces the Appointment of Dr. Markus Weissbach as Chief Operating Officer
DS Biopharma Announces the Appointment of Dr. Markus Weissbach as Chief Operating Officer
HSMN NewsFeed - 6 Jun 2016
Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer
Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer
HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
HSMN NewsFeed - 21 May 2014
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
HSMN NewsFeed - 17 Dec 2013
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
HSMN NewsFeed - 9 Feb 2011
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment From Airmid Inc
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment From Airmid Inc
HSMN NewsFeed - 27 Jul 2009
Ceragenix and MEGAPHARM Enter Into Distribution and Supply Agreement for EpiCeram(R)
Ceragenix and MEGAPHARM Enter Into Distribution and Supply Agreement for EpiCeram(R)
HSMN NewsFeed - 14 Oct 2008
Dr. Reddy's Wholly-Owned Subsidiary Promius Pharma Launches EPICERAM(R) Skin Barrier Emulsion
Dr. Reddy's Wholly-Owned Subsidiary Promius Pharma Launches EPICERAM(R) Skin Barrier Emulsion
HSMN NewsFeed - 18 Sep 2008
Dr. Reddy's Formally Announces its US Specialty Business, Promius Pharma, LLC.
Dr. Reddy's Formally Announces its US Specialty Business, Promius Pharma, LLC.
HSMN NewsFeed - 27 Feb 2008
Manhattan Pharmaceuticals Announces Closing of Joint Venture With Nordic Biotech
Manhattan Pharmaceuticals Announces Closing of Joint Venture With Nordic Biotech
HSMN NewsFeed - 3 Feb 2008
American Academy of Dermatology Research Confirms Genetic Skin Barrier Defect Linked to Eczema
American Academy of Dermatology Research Confirms Genetic Skin Barrier Defect Linked to Eczema
HSMN NewsFeed - 27 Dec 2007
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
HSMN NewsFeed - 19 Nov 2007
Ceragenix and Dr. Reddy's Enter Into Distribution and Supply Agreement for EpiCeram(R)
Ceragenix and Dr. Reddy's Enter Into Distribution and Supply Agreement for EpiCeram(R)
HSMN NewsFeed - 24 Apr 2007
Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints
Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints
HSMN NewsFeed - 9 Nov 2006
Graceway Pharmaceuticals to Acquire 3M Pharmaceuticals Business in North and Latin America
Graceway Pharmaceuticals to Acquire 3M Pharmaceuticals Business in North and Latin America
HSMN NewsFeed - 23 Oct 2006
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
HSMN NewsFeed - 19 Sep 2006
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
HSMN NewsFeed - 8 May 2006
Connetics Names Sunil Patel Vice President, Corporate Development and Strategy
Connetics Names Sunil Patel Vice President, Corporate Development and Strategy
Additional items found! 33
Members Archive contains
33 additional stories matching:
atopic dermatitis
(Password required)
atopic dermatitis
(Password required)
